Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBIT Margin (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed EBIT Margin for 4 consecutive years, with 51.7% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 1457510.0% to 51.7% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.03% through Dec 2025, up 9889.0% year-over-year, with the annual reading at 6.03% for FY2025, 6672.0% up from the prior year.
  • EBIT Margin hit 51.7% in Q4 2025 for Axsome Therapeutics, up from 26.97% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 51.7% in Q4 2025 to a low of 14523.4% in Q4 2024.
  • Historically, EBIT Margin has averaged 1076.12% across 4 years, with a median of 89.7% in 2024.
  • Biggest five-year swings in EBIT Margin: tumbled -1438601bps in 2024 and later skyrocketed 1457510bps in 2025.
  • Year by year, EBIT Margin stood at 245.86% in 2022, then soared by 44bps to 137.39% in 2023, then tumbled by -10471bps to 14523.4% in 2024, then surged by 100bps to 51.7% in 2025.
  • Business Quant data shows EBIT Margin for AXSM at 51.7% in Q4 2025, 26.97% in Q3 2025, and 24.47% in Q2 2025.